Lumos Pharma, Inc. (LUMO): Price and Financial Metrics


Lumos Pharma, Inc. (LUMO): $3.53

0.13 (+3.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LUMO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LUMO Stock Summary

  • For LUMO, its debt to operating expenses ratio is greater than that reported by just 5.51% of US equities we're observing.
  • With a year-over-year growth in debt of -50.86%, LUMOS PHARMA INC's debt growth rate surpasses just 5.35% of about US stocks.
  • Revenue growth over the past 12 months for LUMOS PHARMA INC comes in at 2,362%, a number that bests 99.6% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to LUMOS PHARMA INC, a group of peers worth examining would be RYTM, BYSI, ALBO, PTN, and HCWB.
  • LUMO's SEC filings can be seen here. And to visit LUMOS PHARMA INC's official web site, go to www.lumos-pharma.com.

LUMO Valuation Summary

  • In comparison to the median Healthcare stock, LUMO's EV/EBIT ratio is 85.22% lower, now standing at 1.5.
  • Over the past 137 months, LUMO's price/sales ratio has gone down 26.

Below are key valuation metrics over time for LUMO.

Stock Date P/S P/B P/E EV/EBIT
LUMO 2023-01-30 24.1 0.4 -1.0 1.5
LUMO 2023-01-27 23.5 0.4 -1.0 1.5
LUMO 2023-01-26 24.3 0.4 -1.1 1.5
LUMO 2023-01-25 24.4 0.4 -1.1 1.5
LUMO 2023-01-24 24.5 0.4 -1.1 1.5
LUMO 2023-01-23 23.4 0.4 -1.0 1.5

LUMO Growth Metrics

    Its year over year revenue growth rate is now at 131.97%.
  • Its 2 year cash and equivalents growth rate is now at 1.09%.
  • Its 4 year net cashflow from operations growth rate is now at 56.26%.
Over the past 49 months, LUMO's revenue has gone down $21,139,000.

The table below shows LUMO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.231 -26.625 -28.456
2022-06-30 0.734 -28.145 -28.693
2022-03-31 0.341 -27.269 -29.519
2021-12-31 0.23 -29.648 -30.43
2021-09-30 0.05 -30.8 -27.204
2021-06-30 0.124 -23.368 -17.951

LUMO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LUMO has a Quality Grade of D, ranking ahead of 21.86% of graded US stocks.
  • LUMO's asset turnover comes in at 0.001 -- ranking 434th of 681 Pharmaceutical Products stocks.
  • INVA, RETA, and SUPN are the stocks whose asset turnover ratios are most correlated with LUMO.

The table below shows LUMO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.001 1 -1.992
2021-03-31 0.001 1 -0.861
2020-12-31 0.001 1 -0.498
2020-09-30 0.004 1 -0.644
2020-06-30 0.005 1 -1.373
2020-03-31 0.007 1 -2.610

LUMO Price Target

For more insight on analysts targets of LUMO, see our LUMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.00 Average Broker Recommendation 1.42 (Moderate Buy)

LUMO Stock Price Chart Interactive Chart >

Price chart for LUMO

LUMO Price/Volume Stats

Current price $3.53 52-week high $10.27
Prev. close $3.40 52-week low $2.95
Day low $3.48 Volume 18,601
Day high $3.61 Avg. volume 17,681
50-day MA $3.81 Dividend yield N/A
200-day MA $7.01 Market Cap 29.64M

Lumos Pharma, Inc. (LUMO) Company Bio


Lumos Pharma, Inc. operates as a biopharmaceutical company. The Company discovers, develops, and commercializes therapeutics for patients and families living with rare diseases. Lumos Pharma operates worldwide.


LUMO Latest News Stream


Event/Time News Detail
Loading, please wait...

LUMO Latest Social Stream


Loading social stream, please wait...

View Full LUMO Social Stream

Latest LUMO News From Around the Web

Below are the latest news stories about LUMOS PHARMA INC that investors may wish to consider to help them evaluate LUMO as an investment opportunity.

Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023

12th Annual Corporate Access Event Register for in-person meetings with Lumos Pharma AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 12th Annual LifeSci Partners Corporate Access Event held in San Francisco January 9-11, 2023. Lumos Pharma will host in-person one-on

Yahoo | January 3, 2023

KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients

AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6th to review the Company’s interim data from two Phase 2 trials evaluating oral LUM-201 in moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD). Andrew Dauber, MD, MMSc, Chief of Endocrinology, Children’s National Hospital, and Fernando Cassorla

Yahoo | December 12, 2022

Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data from our Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD). The KOL webinar will take place on December 6th at 2:00 PM EST. Event:KO

Yahoo | November 29, 2022

Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34th Annual Healthcare Conference November 29th through December 1st. Event: Piper Sandler 34th Annual Healthcare Conference – November 29th – December 1stPresentat

Yahoo | November 22, 2022

Lumos Pharma, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:LUMO)

The following slide deck was published by Lumos Pharma, Inc.

Seeking Alpha | November 21, 2022

Read More 'LUMO' Stories Here

LUMO Price Returns

1-mo -11.31%
3-mo -60.91%
6-mo -59.31%
1-year -64.05%
3-year -76.37%
5-year -94.24%
YTD -2.22%
2022 -47.91%
2021 -80.59%
2020 56.83%
2019 66.45%
2018 -81.26%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9394 seconds.